Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Arbutus Biopharma Corporation
Age
18–60
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Chronic hepatitis B virus infection with documentation at least 6 months prior to screening
Subjects must have been receiving either TAF, TDF (or equivalent), or ETV consistently for ≥12 months prior to dosing Day 1
HBV DNA \<LLOQ at Screening
HBsAg between 100 and 5,000 IU/mL at Screening
Subjects must be HBeAg-negative at Screening
Fibroscan® result of ≤8.5 kPa within 6 months prior to dosing Day 1
Medically stable based on physical examination, medical history, vital signs, laboratory values, and 12-lead Electrocardiogram (ECG) at screening
You may not be if
Evidence of co-infection with hepatitis A, C, D or E virus or human immunodeficiency virus (HIV) at screening
History of any clinically significant medical condition associated with chronic liver disease, cirrhosis, evidence of decompensated liver disease, or findings suggestive of hepatocellular carcinoma (HCC) at any time
Contraindications to the use of Peg-IFNα-2a or incapable of self-administration or assisted administration of Peg-IFNα-2a
Previous treatment with an experimental HBV-directed RNA-interference or antisense oligonucleotide product.
Clareo Health | Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection
